GE HealthCare launched the CareIntellect for Oncology, an artificial intelligence application designed to rescue oncologists from much hassle in the diagnosis and treatment of cancer patients. The new technology will bring more relief regarding predominant busy work as massive patient data management and allow healthcare professionals to spend much time with the patients.
CareIntellect for Oncology is meant to concisely summarize patient histories, track disease progression, and rapidly identify prospective clinical trials for patients. GE HealthCare’s Global Chief Science and Technology Officer, Dr. Taha Kass-Hout added that the application will work towards saving clinician time reviewing tedious and often conflicting medical records, where vast amounts of healthcare data occur in many different formats and sources. Moreover, the Deloitte report claims that while hospitals are generating as much as 97% data of no use simply because it is fragmental.
“It’s very time-consuming and frustrating for these clinicians,” said Dr. Kass-Hout in a recent interview. The new tool is set up to give oncologists a panoramic view of clinical reports and instantly draw attention to any deviations in treatment, like missed lab tests, to help intervene in good time.
And CareIntellect may speed up the process of choosing appropriate clinical trials for specific patients — time-consuming and labor-intensive because otherwise, it will require manual searching against numerous criteria forever. As per Chelsea Vane, Vice President, Digital Products, GE HealthCare, “This could be quite time-saving for oncologists so that they can concentrate their attention on clinical care rather than on administrative work.”
The new device was originally slated for a 2025 U.S. release, primarily in prostate and breast cancer, whose performance Tampa General Hospital is set to measure. CareIntellect cloud-based application will likely boost sustained revenue for GE HealthCare.
To complement those efforts, GE HealthCare said on Monday that five additional AI products are planned in partnership with CareIntellect. Among them are a collaborative agent solution for artificial intelligence and tools designed to predict the recurrences of breast cancer and improve mammography screenings.
It solicits healthcare organizations to ensure improvement and regulatory compliance in bettering their offerings. The company takes a strategic approach toward business. Health Companion is one of the initiatives, which has been dubbed whereby a team of AI agents would be extended to clinicians in real-time support across all domains including radiology and pathology.
Through the integration of these complex technologies, GE HealthCare will be at the top to revolutionize the quality of cancer care and make the most of the treatment outcomes for healthcare providers and patients with difficult paths.
Read More: Click Here
